Maravai LifeSciences (NASDAQ:MRVI) Shares Up 6.2% – Time to Buy?

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)’s stock price rose 6.2% during mid-day trading on Friday . The company traded as high as $4.12 and last traded at $4.20. Approximately 1,813,332 shares were traded during mid-day trading, a decline of 16% from the average daily volume of 2,163,016 shares. The stock had previously closed at $3.95.

Analyst Ratings Changes

MRVI has been the subject of a number of recent research reports. William Blair reiterated a “market perform” rating on shares of Maravai LifeSciences in a report on Friday, November 8th. The Goldman Sachs Group cut Maravai LifeSciences from a “neutral” rating to a “sell” rating and cut their price target for the company from $7.00 to $4.25 in a research note on Thursday, December 5th. Guggenheim assumed coverage on Maravai LifeSciences in a research note on Thursday, December 19th. They issued a “neutral” rating on the stock. Wolfe Research assumed coverage on Maravai LifeSciences in a research note on Thursday, November 14th. They issued a “peer perform” rating on the stock. Finally, Robert W. Baird cut their price target on Maravai LifeSciences from $10.00 to $9.00 and set an “outperform” rating on the stock in a research note on Friday, November 8th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Maravai LifeSciences currently has a consensus rating of “Hold” and a consensus target price of $10.28.

Maravai LifeSciences Price Performance

The stock has a 50-day moving average price of $5.06 and a 200 day moving average price of $6.66. The company has a debt-to-equity ratio of 0.89, a current ratio of 10.74 and a quick ratio of 9.94. The firm has a market cap of $1.04 billion, a price-to-earnings ratio of -2.51 and a beta of -0.08.

Insider Transactions at Maravai LifeSciences

In other news, General Counsel Kurt Oreshack sold 25,000 shares of Maravai LifeSciences stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $5.03, for a total transaction of $125,750.00. Following the sale, the general counsel now owns 167,618 shares in the company, valued at approximately $843,118.54. The trade was a 12.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.63% of the company’s stock.

Hedge Funds Weigh In On Maravai LifeSciences

Several institutional investors have recently added to or reduced their stakes in the stock. Delta Investment Management LLC increased its position in Maravai LifeSciences by 285.4% in the 4th quarter. Delta Investment Management LLC now owns 332,993 shares of the company’s stock valued at $1,815,000 after acquiring an additional 246,592 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Maravai LifeSciences by 22.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 251,214 shares of the company’s stock valued at $1,369,000 after acquiring an additional 45,454 shares during the period. Systematic Financial Management LP increased its position in Maravai LifeSciences by 2.3% in the 4th quarter. Systematic Financial Management LP now owns 1,649,544 shares of the company’s stock valued at $8,990,000 after acquiring an additional 37,383 shares during the period. Sherbrooke Park Advisers LLC acquired a new position in Maravai LifeSciences in the 4th quarter valued at about $78,000. Finally, ProShare Advisors LLC increased its position in Maravai LifeSciences by 89.8% in the 4th quarter. ProShare Advisors LLC now owns 55,488 shares of the company’s stock valued at $302,000 after acquiring an additional 26,251 shares during the period. Institutional investors and hedge funds own 50.25% of the company’s stock.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.